33 results about "Primary isolate" patented technology

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies. This invention further provides: methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion; and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion.

The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and / or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and / or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.

This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically, antibodies expressed by clones, Clone 7 containing the recombinant genes B4DIVHv1 / VK1CHO#7, Clone 16 containing the recombinant genes B4DIVHv1 / VK1#16, and clone 21 containing the recombinant genes B4DIVHv1 / VK1#21, are derived from mouse monoclonal B4 antibody (mAb B4). The antibodies were produced by removing particular murine determinants recognized as foreign by the human immune system. These recombinant antibodies were generated by the chimerization and deimmunization of the Fv region of mouse monoclonal antibody (mAb) B4. For improved safety, the coding sequence may further be mutated to express an aglycosylated IgG1 antibody that is unable to bind complement. The deimmunized antibodies retain the specificity of the murine mAb B4 for a receptor complex involving CD4 on the surface of the host T cells, and retain the characteristic ability of mAb B4 to neutralize primary isolates of HIV.

The invention relates to methods for testing the response of spheroids to exposure with therapeutics. Preferably the spheroids are derived from primary isolate biological tissue and / or cell-containing bodily fluid. Further embodiments relate to spheroid sections and arrays including kits suitable for carrying out the method according to the present invention.

This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against a broad spectrum of HIV-1 isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-1. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-1 primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-1 entry into cells, as well as methods of treatment using the inhibitors.

A virus neutralizing level of antibodies to a primary HIV isolate is generated in a host by a prime-boost administration of antigents. The primary antigen is a DNA molecule encoding an envelop glycoprotein of a primary isolate of HIV-1 while the boosting antigen is either a non-infectious, non-replicating HIV-like particle having the envelope glycoprotein of a primary isolate of HIV-1 or an attenuated viral vector expressing an envelope glycoprotein of a primary isolate of HIV-1.

The invention relates to isolated monoclonal antibodies which specifically bind to the C-terminal heptad repeat region of gp41 (HR2) and neutralize an HIV-1 primary isolate.

The invention provides a method for isolating the avian metapneumovirus. The invention adopts the mixed cells of the trachea and lung tissue of hatched SPF chicken embryos aged 17 to 19 days to culture the avian metapneumovirus. On the basis of the traditional method of separating and culturing one clinically ill sample and one sensitive cell at a time, the present invention successfully improves the in vitro culture conditions of AMPV through the same culture system, the separation and passage method of two mixed cells, and significantly improves the separation of AMPV rate, reducing the number of passages.

The invention relates to the technical field of stem cell culture, in particular to a primary isolated culture method for amniotic fluid mesenchymal stem cells. The method includes that according to a differential attachment principle, endothelial cells are enabled to grow along a wall under proper conditions while the mesenchymal stem cells are not adhered to the wall yet. By accurate control of culture time, culture solution containing the amniotic fluid mesenchymal stem cells is transferred after wall adherence of the endothelial cells is finished, and the culture solution is subjected to subculturing to obtain the amniotic fluid mesenchymal stem cells. The method is simple in operation, less devices are required, manual scraping operations are avoided, and accordingly cell damages and contamination are avoided. According to detection results, viability of the amniotic fluid mesenchymal stem cells contained in the culture solution acquired at the step 1 is not lower than 89.28%; after three generations, flow cytometry detection results show that surface antibodies of the cells still accord with characteristics of the stem cells, and differentiating tendency is avoided.

The invention discloses a process for the separation and preparation of refined high-purity hydrocortisone, using low-toxic solvent dichloromethane instead of dichloroethane, one separation process in the process: the weight ratio of raw materials is crude hydrocortisone: dichloromethane Methane:methanol:water=1:6.6-11.9:1.68-3.16:3-3.5. Secondary separation process: the weight ratio of raw materials is hydrocortisone primary isolate: dichloromethane: methanol: water=1: 6.7~7.5: 1.6~2: 3~3.5; hydrocortisone crude product, dichloromethane Add methane, methanol, and water into the reaction tank according to the weight ratio, raise the temperature and reflux, lower the temperature, add a certain amount of water to dilute, and let it stand still. After two separation processes, the high-purity hydrocortisone is obtained after refining.